Laura Hummers is a Rheumatology/Immunology physician affiliated with Johns Hopkins University. OpenAlex indexes 251 publications with 10,175 citations (h-index 53); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 N Wolfe St
Baltimore, MD 212870005
Telephone
410-955-3052Registry record last updated 8 Feb 2013.
Clinical trials
- Lab Study of MQX-503 in Treatment of Raynaud's
Sponsor: MediQuest Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20254 payments
- Boehringer Ingelheim International GmbHProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20241 payment$16,110openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
45.6%Proton pump inhibitor27%Omeprazole39%Pantoprazole Sodium34%Esomeprazole Magnesium18%Dexlansoprazole Dr10%Part D<11 patientsH2 blocker10.1%Famotidine100%Part D≥17 patients+ 2 more classes in this area
Cardiovascular
15%Calcium channel blocker10.3%Amlodipine Besylate80%Felodipine Er20%Part D<11 patientsAngiotensin receptor blocker (ARB)4.8%Losartan Potassium100%Part D<11 patientsCancer & immunology
14.7%Thalidomide Analog7.5%Lenalidomide73%Pomalyst27%Part D<11 patientsFolate Analog Metabolic Inhibitor5.1%Methotrexate100%Part D≥11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2005–2009 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
Annals of the Rheumatic Diseases
2020 - Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer
Annals of the Rheumatic Diseases
2018 - Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed by the COMPASS-31 Questionnaire
The Journal of Rheumatology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Roger Blumenthal, MD
Johns Hopkins University
Erin Michos, MD
Johns Hopkins University
Morgan Grams, MD
Johns Hopkins University
Mario Eisenberger, MD
Johns Hopkins University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”